BLTE

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

• Belite Bio submits marketing authorization applications for tinlarebant to multiple markets through the Access Consortium pathway for Stargardt disease type 1Oct 14, 2026
• Belite Bio submitted a New Drug Application in Japan for tinlarebant under the Sakigake designation for Stargardt disease type 1Sep 8, 2026
• Belite Bio completed enrollment in DRAGON II trial of tinlarebant for Stargardt DiseaseJan 27, 2026
• Belite Bio announces China NMPA agrees to new drug application with priority review based on interim analysis results for treatment of Stargardt disease with TinlarebantOct 15, 2025
• Belite Bio announces completion of DRAGON, a 2-year Phase 3 trial of oral Tinlarebant in treatment of Stargardt diseaseSep 12, 2025